Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Randomized study. Patients with coronary artery disease equivalent will be randomized to
receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day.
Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment.
Hypothesis is that ezetimibe will lower oxidized LDL